Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18394555 
Geron I, et al. (2008) Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 13, 321-30 18394555
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Epo increase
LY294002 Epo inhibit treatment-induced increase
AG490 Epo no effect upon treatment-induced increase
TG101348 Epo inhibit treatment-induced increase

S310-p - GATA1 (human)
Orthologous residues
GATA1 (human): S310‑p, GATA1 (mouse): S310‑p, GATA1 (rat): S310‑p, GATA1 (chicken): S216‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Epo increase
LY294002 Epo inhibit treatment-induced increase
AG490 Epo inhibit treatment-induced increase
TG101348 Epo inhibit treatment-induced increase

Y694-p - STAT5A (human)
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): , STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Epo increase
LY294002 Epo no effect upon treatment-induced increase
AG490 Epo inhibit treatment-induced increase
TG101348 Epo inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.